Case Analysis—Pfizer

• complete an analysis to identify the critical issues of the business case and
• Perform pestle analysis
• perfume the SWOT analysis

. These questions can serve as a starting point for your analysis:

• Pfizer has twice attempted to merge with another pharmaceutical company, and both times the mergers have failed. Why is Pfizer so eager to merge? Why did these attempts fail? What segments of the external environment have influenced this situation?
• Pfizer and other big pharma companies have been harshly criticized for charging “exorbitant” prices for some of their drugs, but Pfizer says its prices are justified. Debate the issue, examining both viewpoints. Is this a smart pricing strategy or not?
• Pfizer has twice attempted to merge with another pharmaceutical company, and both times the mergers have failed. Why is Pfizer so eager to merge? Why did these attempts fail? What segments of the external environment have influenced this situation?
• Pfizer and other big pharma companies have been harshly criticized for charging “exorbitant” prices for some of their drugs, but Pfizer says its prices are justified. Debate the issue, examining both viewpoints. Is this a smart pricing strategy or not?
• summarize your analysis and recommendations in a brief report

Your report should include the following:

• Critical Questions: List one to two questions that would contribute to a meaningful discussion about the case in class. These questions should get at the deeper issues of the case, lead to critical analysis of possible solutions, and help us identify takeaways and learning points tPrinciples and Application: List one to two takeaways from your analysis that apply to other projects in the class, your life, and your future work. They should help you identify how to better apply the strategies and principles that you learned this week in the reading.
• The main points of the case: Briefly summarize the most important aspects of the case. Include the key players, the background that led to where the company is at, and other considerations.
• A summary of your analysis with evidence: Include the results of any analysis you conducted, including external analysis, internal analysis, PEST and SWOT analyses, etc. Summarize strengths, weaknesses, and threats for the company.
• Strategy: Identify three to four recommendations for resolving major issues and optimizing opportunities. List the pros and cons of each option and identify which one you recommend the company adopts. Justify your choice in reference to principles in the course textbook and the results of your analysis.
• Strategy Implementation: Provide steps the company would need to take to implement the proposed strategy, including changes to company structure, incentives, control, etc.
• hat we can apply in the future.
• Additional Resources

These are additional resources that you can use during your analysis.

• Reuters’s company profile gives in-depth background on Pfizer’s current financials, leadership, valuation, news, and more: Pfizer Inc. PFE.NLinks to an external site..
• Yahoo! Finance’s company profile offers additional background on Pfizer’s current financials, leadership, valuation, news, and more: Pfizer Inc. (PFE)Links to an external site..
• Investors tried to pressure Pfizer into splitting into two companies in 2016, but the firm refused and explained why: Drugmaker Pfizer decides not to break up businessLinks to an external site..
• The North Jersey Record reported on a drug pricing conspiracy lawsuit against Pfizer and several other drug companies from May 2019: Teva, Pfizer, Sandoz among 20 companies accused of illegally hiking generic drug pricesLinks to an external site..
• In April 2019, The Motley Fool described three obstacles that could negatively impact Pfizer’s future success: The 3 Greatest Risks Pfizer FacesLinks to an external site.
• In March 2017, CNBC interviewed Pfizer’s former CEO Henry McKinnell, who advocated for legal changes for the industry:Former Pfizer CEO: Drugs Prices Expensive Because Research Expensive | Power Lunch | CNBC